GlassScriptPhysician profile
David M Felig
NPI 1780681866
$8,347.61
in general payments reported to CMS, 2019-2025
44 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $288 · 2021: $462 · 2022: $1,397 · 2023: $2,702 · 2024: $1,269 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Consulting Fee: $1,250 · Education: $13.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,304.14 |
| Consulting Fee | $1,250.00 |
| Education | $13.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $1,483.48 | 2022-2025 | Ibsrela |
| Abbvie INC. | $1,229.28 | 2019-2025 | |
| Janssen Biotech, INC. | $762.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $731.67 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.93 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $534.22 | 2021-2024 | Zeposia |
| Pfizer INC. | $427.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $240.15 | 2019-2024 | Dificid, Zinplava |
| Ferring Pharmaceuticals INC. | $209.31 | 2019-2025 | Rebyota, Clenpiq |
| Lilly USA, LLC | $203.24 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $173.22 | 2019-2024 | Linzess |
| Ethicon US, LLC | $169.37 | 2022 | |
| Intercept Pharmaceuticals, INC. | $148.08 | 2019-2025 | |
| Genzyme Corporation | $128.87 | 2023-2025 | |
| Madrigal Pharmaceuticals | $124.58 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $90.83 | 2019-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $84.17 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $83.34 | 2023-2024 | Idacio |
| Exact Sciences Corporation | $78.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $69.89 | 2025 | Zenpep |
| Celltrion USA INC. | $67.00 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $64.92 | 2022-2025 | Dupixent |
| W. L. Gore & Associates, INC. | $53.98 | 2021-2023 | Gore Cardioform Septal Occluder |
| Gilead Sciences, INC. | $47.58 | 2021-2025 | |
| Cumberland Pharmaceuticals, INC. | $46.96 | 2023-2025 | Kristalose, Caldolor |
| Medtronic, INC. | $42.23 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $34.75 | 2024-2025 | Iqirvo |
| Vivus LLC | $31.28 | 2025 | Pancreaze, Qsymia |
| Novo Nordisk INC | $29.35 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $27.89 | 2021-2022 | |
| Allergan, INC. | $22.99 | 2019 | |
| Digestive Care, INC. | $22.41 | 2022 | |
| Qol Medical, LLC | $21.80 | 2025 | Sucraid |
| Biocon Biologics INC | $21.70 | 2025 | Yesintek |
| Sanofi US Services INC. | $21.47 | 2025 | |
| Blueprint Medicines Corporation | $20.85 | 2024 | Ayvakit |
| Boston Scientific Corporation | $19.68 | 2022 | |
| Intra-Sana Laboratories | $15.37 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Redhill Biopharma INC. | $14.93 | 2022 | |
| Shire North American Group INC | $13.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.13 | 2023 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $12.75 | 2023 | Zeposia |
| Ucb, INC. | $11.27 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Felig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.